Home » Topics » Disease categories and therapies » Dermatologic

Dermatologic
RSS

Hyal's treatment for sun spots approved in the U.K.

July 3, 1997

Celtrix's SomatoKine enters phase II feasibility study for the treatment of burns

July 2, 1997

Cellegy's antiwrinkling product enters clinical trials

July 1, 1997

Preclinical results with Anika's INCERT promising

July 1, 1997

Antipruritogenic effect of Kochia Fructus extract and active components

June 26, 1997

Agents for psoriasis and cancers from Roche

June 20, 1997

RXR-selective compounds disclosed by Allergan

June 20, 1997

General Hospital Corp. and Shiseido disclose psoriastatin polypeptides

June 18, 1997

Tazorac approved in the U.S.

June 18, 1997

La Jolla Cancer Res. Found. discloses integrin-binding peptides

June 17, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.